Bayhill Therapeutics, Inc. to Present Correlation of Antibodies with Clinical Response to Treatment with BHT-3009 in Multiple Sclerosis

Published: Oct 14, 2010

PALO ALTO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment. The abstract to be presented entitled “Baseline plasma anti-MBP antibody levels correlate with subject response to BHT-3009, a novel, antigen-specific tolerising DNA vaccine therapy for MS patients,” is being shown as poster #417 in poster session 1.

Back to news